Abstract
Androgenetic alopecia significantly affects individuals’ quality of life, creating a need for better therapeutic strategies. Hair transplant surgery plays a key role in treating hair loss, with adjuncts like PRP and meso-cocktails explored to enhance results and procedure longevity. A prospective, single-blind study involved 112 males aged 25-50 years with Norwood-Hamilton grade IV-VI alopecia. Patients were randomly divided into two groups receiving different transplant methods. In Stage I, hair condition was evaluated, and QR678 Neo® was administered intradermally in Group A. Stage II involved hair transplantation surgery with diluted QR678 Neo® for graft preservation. Post-transplantation (Stage III) included additional QR678 Neo® administration in Group A. Evaluation methods consisted of global photographic assessment and videomicroscopy to measure hair growth and density. Group A (QR678 Neo®) demonstrated significant improvements in regrowth, density, and shaft diameter compared to Group B (conventional transplant). By Stage III, Group A had higher Global Photographic Assessment scores (8.87) and terminal hair count (181.02), with statistically significant differences (p < .001). The study suggests that QR678 Neo® improves outcomes and offers a promising treatment option for androgenetic alopecia.